These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 15561813

  • 1. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun 20; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 4. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul 20; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 5. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L.
    Clin Breast Cancer; 2005 Dec 20; 6(5):446-54. PubMed ID: 16381629
    [Abstract] [Full Text] [Related]

  • 6. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA, Tchekmedyian NS.
    Oncology (Williston Park); 2002 Oct 20; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
    Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D.
    Oncologist; 2005 Sep 20; 10(8):642-50. PubMed ID: 16177289
    [Abstract] [Full Text] [Related]

  • 8. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul 20; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 9. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Jul 20; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 10. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R, Lillie T, Tomita D, Balducci L.
    Oncologist; 2007 May 20; 12(5):584-93. PubMed ID: 17522247
    [Abstract] [Full Text] [Related]

  • 11. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 20; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 12. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 20; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 13. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Jan 20; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 14. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 20; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 15. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008 Jun 20; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

  • 16. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
    Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T.
    BMC Cancer; 2010 Oct 25; 10():581. PubMed ID: 20973982
    [Abstract] [Full Text] [Related]

  • 17. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J.
    Oncologist; 2007 Oct 25; 12(10):1253-63. PubMed ID: 17962619
    [Abstract] [Full Text] [Related]

  • 18. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul 25; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

  • 19. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 25; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D, Canon JL, Mateos MV, Hedenus M, Rossi G, Taylor K.
    Curr Med Res Opin; 2007 Jun 25; 23(6):1387-401. PubMed ID: 17559735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.